TrialsgrambetaRCTs are beautiful

IDNT

2001

Irbesartan Diabetic Nephropathy Trial

In 1,715 patients with type 2 diabetes and nephropathy, irbesartan reduced progression of the renal composite compared with amlodipine or placebo.

Result

Primary endpoint: Doubling of creatinine, ESRD or death

Irbesartan vs placebo HR 0.80 (p=0.02); vs amlodipine HR 0.77 (p=0.006).

Original publication
Subtopic
RAAS blockade
Design
Double-blind RCT, three arms
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Lewis EJ, et al. N Engl J Med. 2001;345(12):851-860.doi 10.1056/NEJMoa011303

Discussion & critique

Showed renoprotection is independent of the calcium-channel-blocker comparator and of the blood-pressure effect.

Discussed in podcasts